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Abstract
Neuraminidase (NA) mutations conferring resistance to NA inhibitors were believed to compromise influenza virus fitness.
Unexpectedly, an oseltamivir-resistant A/Brisbane/59/2007 (Bris07)-like H1N1 H275Y NA variant emerged in 2007 and
completely replaced the wild-type (WT) strain in 2008–2009. The NA of such variant contained additional NA changes
(R222Q, V234M and D344N) that potentially counteracted the detrimental effect of the H275Y mutation on viral fitness.
Here, we rescued a recombinant Bris07-like WT virus and 4 NA mutants/revertants (H275Y, H275Y/Q222R, H275Y/M234V
and H275Y/N344D) and characterized them in vitro and in ferrets. A fluorometric-based NA assay was used to determine
Vmax and Km values. Replicative capacities were evaluated by yield assays in ST6Gal1-MDCK cells. Recombinant NA proteins
were expressed in 293T cells and surface NA activity was determined. Infectivity and contact transmission experiments were
evaluated for the WT, H275Y and H275Y/Q222R recombinants in ferrets. The H275Y mutation did not significantly alter Km
and Vmax values compared to WT. The H275Y/N344D mutant had a reduced affinity (Km of 50 vs 12 mM) whereas the
H275Y/M234V mutant had a reduced activity (22 vs 28 U/sec). In contrast, the H275Y/Q222R mutant showed a significant
decrease of both affinity (40 mM) and activity (7 U/sec). The WT, H275Y, H275Y/M234V and H275Y/N344D recombinants had
comparable replicative capacities contrasting with H275Y/Q222R mutant whose viral titers were significantly reduced. All
studied mutations reduced the cell surface NA activity compared to WT with the maximum reduction being obtained for
the H275Y/Q222R mutant. Comparable infectivity and transmissibility were seen between the WT and the H275Y mutant in
ferrets whereas the H275Y/Q222R mutant was associated with significantly lower lung viral titers. In conclusion, the Q222R
reversion mutation compromised Bris07-like H1N1 virus in vitro and in vivo. Thus, the R222Q NA mutation present in the WT
virus may have facilitated the emergence of NAI-resistant Bris07 variants.
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Introduction
Influenza viruses are respiratory pathogens associated with
significant public health consequences. Each year, influenza
epidemics can be responsible for significant morbidity in the
general population and excess mortality in elderly patients and
individuals with chronic underlying conditions. Influenza A viruses
of the H1N1 subtype have been associated with seasonal influenza
epidemics for many decades and, in presence of immunological
pressure, such viruses continue to evolve through genetic
variability which is mainly confined to virus segments encoding
surface glycoproteins i.e., the hemagglutinin (HA) and neuramin-
idase (NA) [1]. Consequently, viral strains to be used in annual
influenza vaccines should be regularly updated to ensure optimal
protection. Besides vaccines, neuraminidase inhibitors (NAI)
including inhaled zanamivir, oral oseltamivir and intravenous
peramivir provide an important additional measure for the control
of influenza infections [2]. These antivirals target the active center
of the influenza NA molecule, which is constituted by 8 functional
(R-118, D-151, R-152, R-224, E-276, R-292, R-371, and Y-406;
N2 numbering) and 11 framework (E-119, R-156, W-178, S-179,
D-198, I-222, E-227, H-274, E-277, N-294, and E-425; N2
numbering) residues that are largely conserved among influenza A
and B viruses [3]. However, the emergence of NAI-resistant
viruses, as a result of drug use or due to circulation of natural
variants, may compromise the clinical utility of this class of anti-
influenza agents.
The H275Y (H274Y in N2 numbering) NA mutation conferring
resistance to oseltamivir and peramivir has been detected with
increasing frequency in seasonal A/H1N1 viruses since 2007 to
the extent that almost all characterized A/Brisbane/59/2007-like
(Bris07) (H1N1) influenza strains that circulated worldwide during
the 2008–09 season were H275Y variants [4,5]. Interestingly, this
drug-resistant strain seemed to have emerged independently of
NAI use [6,7]. The rapid dissemination of the H275Y Bris07
variants in the absence of antiviral pressure suggests that the
H275Y NA mutation may not compromise viral fitness and
transmissibility in this recent H1N1 viral background. This
contrasts with previous studies that analyzed the role of the
H275Y mutation using older (A/Texas/36/91 [8] and A/New
Caledonia/99/01 [9]) drug-selected H1N1 variants. Recent
reports by our group and others have confirmed the differential
impact of the H275Y mutation on viral fitness and enzymatic
properties in the context of old and recent influenza H1N1 isolates
PLoS Pathogens | www.plospathogens.org 1 December 2011 | Volume 7 | Issue 12 | e1002431[10,11]. In an attempt to provide a molecular explanation for this
observation, previous authors suggested that secondary NA
mutations such as D344N that emerged in H1N1 variants isolated
after the 2006–07 season were associated with higher NA activity
and affinity and could have facilitated the emergence of the
H275Y mutation [11,12]. Such drug-resistant mutants may have a
better HA-NA balance than the susceptible viruses and indeed
completely replaced them in a short period of time. In addition,
Bloom and colleagues recently described two other secondary NA
mutations at codons 222 and 234 that may have counteracted the
compromising impact of the H275Y mutation [13]. In that study,
the V234M and R222Q mutations were shown to restore the viral
fitness of an A/New Caledonia/20/99 H1N1 variant containing
the H275Y mutation [13].
To further investigate which secondary NA mutations may have
facilitated the introduction of the H275Y mutation in contempo-
rarily seasonal H1N1 viruses and allowed their dissemination, we
developed a reverse genetics system using a clinical Bris07 (H1N1)
isolate as genetic background and evaluated the impact of the
H275Y oseltamivir resistance mutation as well as several potential
compensatory NA mutations on enzyme activity, viral fitness and
transmissibility.
Results
In the present study, five recombinant Bris07 influenza viruses
were generated i.e., the WT virus (containing the putative
permissive mutations) that briefly circulated during the 2007–08
season, the single H275Y oseltamivir-resistant variant and three
double mutants containing the H275Y mutation as well as
reversion of potential permissive mutations (H275Y/Q222R,
H275Y/M234V and H275Y/N344D). NA enzymatic properties
using equivalent titers of recombinants were first analyzed with
determination of relative NA enzymatic activity (Vmax values),
which reflects the total NA activity per virion, and Km values,
which reflect the affinity for the substrate. As shown in Table 1,
the single H275Y mutation had no significant impact on NA
affinity and activity compared to the WT virus in the context of
the Bris07 background. By contrast, the double H275Y/Q222R
mutation was associated with a significant reduction of both NA
affinity (Km of 40.31 vs 11.95 mM, P,0.001) and relative NA
activity (7.01 vs 28.19 U/sec, P,0.001) compared to the WT
(Table 1 and Fig. 1). The H275Y/M234V mutant had a Km value
comparable to that of the WT, whereas its relative NA activity was
significantly reduced (Vmax of 21.89 vs 28.19 U/sec, P,0.05). The
H275Y/N344D mutant showed a significantly reduced affinity
(Km of 50.77 vs 11.95 mM, P,0.001) with no change in NA
activity compared to the WT. When comparing the double
mutants to the single H275Y mutant, the Km values were
significantly increased for the H275Y/Q222R and H275Y/
N344D mutants (P,0.001) whereas only the double H275Y/
Q222R mutant had a significantly lower relative NA activity
(P,0.001).
Using recombinant NA proteins expressed in 293T cells, we
further investigated the impact of NA mutations on the amount of
NA activity at the cell surface. As shown in Fig. 2, all studied
mutations were associated with a significant reduction of total
surface NA activity compared to the WT with relative total surface
activities of 66% (P,0.01), 9.72% (P,0.001), 32.07% (P,0.001)
and 54.89% (P,0.01) for the H275Y, H275Y/Q222R, H275Y/
M234V and H275Y/N344D mutant proteins, respectively. When
compared to the single H275Y mutant, H275Y/Q222R
(P,0.001), H275Y/M234V (P,0.001) and H275Y/N344D
(P,0.05) double mutants also had significantly reduced surface
NA activities. The differences observed in total surface NA activity
between the different recombinant NA proteins may be due to a
decreased number of NA molecules that reached the cell surface or
to less activity per enzyme.
We next determined the phenotype of resistance to NAIs for the
5 recombinant viruses. As expected, the presence of the H275Y
mutation was associated with resistance to oseltamivir (mean fold
increase of 2627 in IC50 values) and peramivir (mean fold increase
of 998) with no impact on zanamivir susceptibility (Table 2).
Interestingly, comparison of the levels of resistance for the double
recombinant mutants versus the single H275Y mutant revealed a
significant reduction in the level of resistance to peramivir for the
double H275Y/Q222R mutant (IC50 of 35.25 nM vs 59.85 nM,
P,0.01). A similar trend was observed for oseltamivir (IC50 of
651.86 nM vs 1024.54 nM) although, in this case, the difference
between IC50 values was not statistically significant.
Viral fitness of recombinant A/Brisbane/59/2007-like viruses
was assessed in vitro using ST6Gal1-MDCK cells. The double
H275Y/Q222R mutant produced viral plaques with a signifi-
cantly reduced area compared to the recombinant WT (0.13 mm
2
vs 0.53 mm
2, P,0.001) whereas the remaining recombinants
generated plaques of comparable sizes (Table 1). Of note, the
reduction in plaque size for the H275Y/Q222R mutant was also
significant compared to that of the single H275Y mutant
(P,0.001). In replication kinetics experiments, the peak viral
titers for all recombinants were obtained at 36 h post-infection (PI)
with viral titers ranging from 5.6610
6 PFU/ml (H275Y/Q222R)
to 5.3610
7 PFU/ml (WT) (Fig. 3). The WT, the single (H275Y)
and the double (H275Y/N344D) mutants had comparable viral
titers at all time points. By contrast, and in accordance with plaque
size data, the double H275Y/Q222R mutant was associated with
a significant reduction in viral titers at 36 h (P,0.001) and 48 h
(P,0.05) PI compared to the WT (Fig. 3). There was also a
significant reduction in the viral titer obtained at 36 h PI for the
double H275Y/M234V mutant compared to the WT (P,0.001).
When compared to the single (H275Y) mutant, viral titers of the
Author Summary
The H275Y neuraminidase (NA) mutation conferring
resistance to oseltamivir was shown to impair old influenza
H1N1 strains both in vitro and in vivo. By contrast, an
oseltamivir-resistant A/Brisbane/59/2007 (Bris07)-like H1N1
H275Y NA variant emerged in 2007 and completely
replaced the wild-type (WT) strain in 2008–2009. This
discrepancy could be attributed to permissive NA muta-
tions (R222Q, V234M and D344N) that were identified in
most Bris07-like oseltamivir-resistant variants. To verify this
hypothesis, we developed a reverse genetics system for a
sensitive Bris07-like isolate (275H) whose NA protein
contains the 3 permissive mutations (222Q, 234M, 344N).
Using mutagenesis, we first introduced the H275Y then
reverted codons at positions 222, 234 and 344. The
resulting 5 recombinants (WT, H275Y, H275Y/Q222R,
H275Y/M234V and H275Y/N344D) were compared with
regard to NA enzyme properties, replicative capacities in
vitro as well as infectivity and contact-transmissibility in
ferrets. Among the studied permissive mutations, Q222R
was associated with a significant reduction of both affinity
and activity of the NA enzyme resulting in a virus with a
reduced replicative capacity in vitro and decreased
replication in lungs of ferrets. Thus, the R222Q mutation
may have been the major permissive NA change that
facilitated the emergence and spread of NAI-resistant
Bris07 variants.
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significantly lower at 36 h (P,0.001).
Intranasal inoculation of ferrets with the WT and two mutant
(H275Y and H275Y/Q222R) Bris07 recombinant viruses resulted
in a febrile response that peaked on day 2 PI (Fig. 4A). The area
under the curve (AUC) of temperatures between days 0 and 6 PI
was similar for the 3 groups of ferrets i.e. 6.8161.19 for the WT
virus, 5.9961.9 for the H275Y/Q222R mutant and 7.2660.55
for the H275Y mutant. There was no significant difference in body
weight between the three groups of animals at any time points
(data not shown). As shown in Fig. 5A, mean viral titers in nasal
wash samples collected on day 2 PI from ferrets infected with the
recombinant WT and the single H275Y mutant were comparable
(4610
562.9610
4 PFU/ml for the WT and 2.6610
568.7610
4
PFU/ml for the H275Y mutant) whereas the H275Y/Q222R
mutant had a reduced mean viral titer (4.6610
464.2610
3 PFU/
ml; P,0.05 vs WT). Similarly, mean viral titers in nasal wash
samples of ferrets infected with the H275Y/Q222R were
significantly lower than those of the H275Y mutant (P,0.05)
and WT virus (P,0.01) on day 4 PI (3.4610
361.7610
3,
1.1610
466.7610
3 and 1.5610
469.6610
2 PFU/ml, respectively).
On the other hand, the three recombinants were associated with
comparable mean viral titers on day 6 PI (2610
264.6610
1 PFU/
ml for the WT, 1.1610
265.8610
1 PFU/ml for the H275Y/
Q222R and 1.3610
268.1610PFU/ml for the H275Y).
All contact ferrets seroconverted for A/Brisbane/59/2007 when
tested 14 days after contact, with geometrical mean hemaggluti-
nation inhibition (HAI) titers of 160633, 1456119 and 95655 for
the WT, H275Y and H275Y/Q222R recombinant viruses,
respectively. A febrile response could be observed on days 4 and
5 in the WT and the H275Y groups, respectively, but not in the
H275Y/Q222R group (Fig. 4B). The AUC of temperatures
between days 2 and 6 PI was similar between groups of ferrets
infected with the recombinant WT (5.2960.34) and its H275Y
variant (4.5460.19) whereas the AUC of the H275Y/Q222R
group was significantly lower than that of the WT group
(4.0960.96; P,0.05). Viral titers in nasal wash samples collected
on days 2, 4 and 6 PI are shown in Fig. 5B. Only the WT virus was
detected on day 2 PI. Mean viral titers were comparable for the
H275Y mutant and the WT virus on days 4 and 6 PI. In contrast,
Figure 1. Neuraminidase (NA) enzyme kinetics of recombinant A/Brisbane/59/2007-like (H1N1) viruses. The rate of substrate
conversion velocity (V0) by NA enzymes from a standardized dose of 10
6 PFU/ml of recombinant virus was determined. The fluorogenic substrate
(MUNANA) was used at final concentrations of 0 to 3000 mM. Fluorescence was measured every 90 sec for 53 min at 37 uC using excitation and
emission wavelengths of 355 and 460 nm, respectively. The data of one representative experiment performed in triplicate is shown.
doi:10.1371/journal.ppat.1002431.g001
Table 1. Neuraminidase enzymatic properties and plaque areas of recombinant A/Brisbane/59/2007-like (H1N1) viruses.
Recombinants Km
a( mM) Relative NA activity (Vmax)
a (U/sec) Vmax ratio vs WT Plaque area (mm
2)
b
WT 11.9562.4 28.1960.74 1.00 0.5360.17
H275Y 16.9262.25 23.8161.95 0.84 0.5060.16
H275Y/Q222R 40.3165.5 *** 7.0160.11*** 0.25 0.1360.06 ***
H275Y/M234V 18.1861.2 21.8961.24* 0.78 0.4960.13
H275Y/N344D 50.7761.0 *** 24.9662.48 0.89 0.5060.15
aValues indicate mean Km and relative NA activity (Vmax) values of a representative experiment performed in triplicate 6 standard deviations (SD).
bValues indicate mean plaque area (N=16) 6 SD.
*P,0.05,
***P,0.001 compared to WT.
doi:10.1371/journal.ppat.1002431.t001
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mean viral titers compared to WT on both day 4
(2.7610
261.2610
2 vs 1.2610
463.5610
3 PFU/ml, P,0.01) and
day 6 PI (3.8610
362.1610
3 vs 1.2610
462.5610
3 PFU/ml,
P,0.01).
Discussion
In this study, we used recombinant viruses derived from a clinical
WT Bris07 strain to demonstrate using both in vitro and ferret
experiments that the R222Q NA mutation was the main but
possibly not the only permissive mutation that allowed the
widespread dissemination of the oseltamivir-resistant H275Y
mutant during the 2007–09 influenza seasons. Although such
mutant seems to have disappeared since the emergence of the
pandemic H1N1 virus in April 2009, understanding the mecha-
nisms leading to the transmission of this unique virus is of great
importance and could have an impact on the future use of NAIs.
The influenza NA protein plays a major role during the viral
replication cycle. Its sialidase activity promotes virion release by
removing sialic residues from viral glycoproteins and infected cells
[14]. The NA enzyme also mediates virus penetration in the mucin
layer of the respiratory tract, facilitating virus spread [15].
Importantly, the catalytic site of the NA enzyme has been shown
to be conserved in all influenza A subtypes and influenza B viruses
[3]. Therefore, the influenza NA protein has been considered as a
suitable target for designing anti-influenza agents for both
prophylactic and therapeutic purposes. Besides its functional role,
the NA protein is a major structural surface glycoprotein that is
exposed to the host immune pressure [14]. The NA gene, like the
HA one, is therefore subject to more genetic variations than the
rest of the influenza genome. Consequently, some amino acid (a.a.)
changes, part of antigenic sites of the NA protein, may significantly
contribute to the emergence of drifted variants, whereas certain
substitutions located in or near the catalytic site may also affect the
NA enzyme properties. For instance, Hensley and colleagues have
recently identified NA mutations conferring resistance to zanami-
vir in variants of an influenza A/Puerto Rico/8/1934 H1N1 virus
that was subjected to anti-HA monoclonal antibodies pressure
[16].
In this study, we focused on a.a. changes that occurred in the
NA protein during the evolution of recent seasonal influenza
H1N1 viruses and that may have been involved in the
development and dissemination of resistance to NAIs. These
changes included the well-known framework H275Y mutation,
responsible for the resistance phenotype to oseltamivir and
peramivir, as well as other substitutions (V234M, R222Q and
D344N) that may have contributed to the emergence and
dissemination of resistance by acting as permissive/compensatory
mutations.
Phylogenetic analyses previously demonstrated that the V234M
mutation was already present in oseltamivir-susceptible A/
Solomon Islands/3/2006 (SI06) viruses [13]. In another report,
NA enzyme properties of SI06 viruses were found to be similar to
those of older oseltamivir-susceptible strains such as A/New
Caledonia/99/2001 in terms of relative NA activity (Vmax) and
affinity (Km) [11]. By contrast, the appearance of the R222Q and
D344N mutations in H1N1 viruses isolated after 2007 was
associated with a significant increase in NA affinity (decreased Km
values) in both 275H and 275Y strains [11]. In accordance with
these observations, we demonstrated a sharp impact for the
Q222R and N344D reversion mutations on Km values using our
Bris07 recombinants (Table 1). Besides its effect on NA affinity, the
Q222R reversion mutation was also associated with a significant
decrease in relative NA activity (Table 1 and Fig. 1) and total NA
activity that was expressed on the cell surface (Fig. 2), in line with
previously-reported results in another viral background [13]. As a
result, the H275Y/Q222R mutant virus was significantly com-
Figure 2. Surface activity of recombinant A/Brisbane/59/2007-
like (H1N1) neuraminidase proteins. 293T cells were transfected
with pCAGGS-PA, -PB1, -PB2, and -NP plasmids in addition to plasmids
expressing the WT or mutant A/Brisbane/59/2007-like neuraminidases
(NA) proteins. At 24 h post-transfection, cells were treated with a non-
lysing buffer and surface NA activity was measured by using the
fluorogenic substrate (MUNANA). Percent surface NA activities were
determined in triplicate experiments 6 standard deviations. **P,0.01
and ***P,0.001 compared to the WT surface NA activity.
doi:10.1371/journal.ppat.1002431.g002
Table 2. Susceptibility profiles of recombinant A/Brisbane/59/2007-like (H1N1) viruses against neuraminidase (NA) inhibitors as
assessed by MUNANA NA inhibition assays.
Recombinants Oseltamivir
a (nM) Zanamivir
a (nM) Peramivir
a (nM)
WT 0.3960.02 0.1860.03 0.0660.01
H275Y 1024.546114.10 0.2760.06 59.8562.42
H275Y/Q222R 651.866116.88 0.1860.04 35.2562.11**
H275Y/M234V 1038.566116.09 0.2060.01 47.8761.33
H275Y/N344D 735.07667.91 0.2860.03 47.1563.76
aValues indicated mean IC50 values of three experiments 6 standard deviations.
**P,0.01 compared to the single H275Y mutant.
doi:10.1371/journal.ppat.1002431.t002
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patterns. Such decreased viral replication of the H275Y/Q222R
mutant was also evident in vivo, resulting in lower viral titers in
nasal wash samples and an absence of febrile response in contact
ferrets. However, the H275Y/Q222R mutant was transmitted to
all naı ¨ve ferrets by direct contact meaning that the combination of
several permissive NA mutations and/or mutations elsewhere in
the viral genome may be necessary to recapitulate the epidemi-
ological observations showing increased transmission of the
oseltamivir-resistant Bris07 virus. Also, it should be noted that
naı ¨ve (non-immune) ferrets may not completely capture the fitness
of Bris07 in humans with pre-existing immunity. Alternatively, the
Q222R mutation could affect airborne transmission which has not
been evaluated in our study. Of note, possibly due to the lower
affinity of Q222R for MUNANA, less NAIs were required for
competitive inhibition of the H275Y/Q222R mutant compared to
the H275Y mutant. Residue 222 is located in the vicinity of the
catalytic site of the N1 enzyme based on 3-D structure analysis
[17]. Thus, substitution of a charged (R) by an uncharged (Q) a.a.
at codon 222 may be the main change that dramatically altered
the NA enzyme properties of recent seasonal H1N1 viruses. Of
interest, only one NA substitution (R194G) was sufficient to restore
the viral fitness of an influenza A/WSN/33 (H1N1) virus
containing the compromising H275Y NA mutation [13].
In addition to the R222Q mutation, a permissive role was also
suggested for V234M and D344N substitutions [11,13]. Interest-
ingly, in a recent report on the evolution of influenza NA genes,
positive epistasis (i.e. combination of mutations that are substan-
tially more beneficial than single mutations alone) was detected in
pairs of codons within the NA gene of the N1 subtype including
2752222, 2752234, and 2752344 [18]. In our study, although
the M234V and N344D reversions were associated with decreased
relative NA activity and affinity, respectively (Table 1 and Fig. 1),
none of these mutations significantly altered the viral fitness in vitro.
Nevertheless, a possible synergy between these mutations and
Q222R cannot be completely excluded.
Our study revealed that the H275Y NA mutation was not
deleterious to fitness in the Bris07 genetic context in contrast to
older H1N1 strains. However, this mutant did not have a
replicative advantage compared to the WT as suggested by
epidemiological studies. Indeed, the recombinant WT virus and its
H275Y variant demonstrated similar replication kinetics during in
vitro experiments. In addition, these recombinants had comparable
infectivity and contact transmissibility in ferrets. Thus, the
presence of the permissive mutations (R222Q, V234M and
D344N) in the NA protein of our WT strain was apparently not
sufficient to alter the viral fitness to the level that a compensatory
change, such as the H275Y mutation, would be necessary.
Therefore, we believe that changes in the NA gene alone may
not provide a complete explanation for the emergence and spread
of the oseltamivir-resistant H275Y Bris07 variant. Other changes
in the genome might have been involved in this event. For
instance, Yang and colleagues recently demonstrated that the
dominant H275Y variant that emerged in Taiwan in 2007–2008
was a result of intra-subtypic reassortments between HA, NA, PB2
and PA genes from one clade (clade 2B) and the remaining 4 genes
from another one (clade 1) [19]. Furthermore, the H275Y NA
substitution and other changes in NA, HA, PB1 and PB2 proteins
occurred in that background [19]. Thus, it would be also
interesting to assess the effect of HA and particularly polymerase
mutations that differed between WT and H275Y mutant clinical
Bris07 isolates on replicative capacities and transmissibility.
Despite the fact that the secondary mutations described here
were not investigated individually but in conjunction with H275Y,
our study provides a comprehensive analysis of relevant permissive
NA mutations in the contemporarily seasonal H1N1 background.
This included in vitro characterization, assessment of viral fitness
and contact transmission in ferrets as well as NA enzyme
Figure 3. Replication kinetics of recombinant A/Brisbane/59/2007-like viruses in vitro. Confluent ST6Gal1-MDCK cells were infected with
recombinant viruses at a multiplicity of infection (MOI) of 0.001 PFU/cell. Supernatants were harvested at 12 h, 24 h, 36 h, 48 h and 60 h post-
infection and titrated by standard plaque assays. The mean values for three experiments with standard deviations are presented. *P,0.05 and
***P,0.001 for differences in viral titers when compared to the recombinant WT virus.
doi:10.1371/journal.ppat.1002431.g003
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PLoS Pathogens | www.plospathogens.org 5 December 2011 | Volume 7 | Issue 12 | e1002431Figure 4. Body temperatures of infected and contact ferrets. Body temperatures were recorded by rectal thermometer during 10 days post-
inoculation in groups of 4 index ferrets infected with 1.25610
5 PFU of recombinant A/Brisbane/59/2007-like wild-type (WT) virus as well as H275Y and
H275Y/Q222R mutants (A) and in groups of 4 naı ¨ve ferrets that were placed in direct contact with index ferrets 24 h later (B).
doi:10.1371/journal.ppat.1002431.g004
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clearly demonstrated the positive impact of one specific NA
substitution (i.e. R222Q) in conjunction with the oseltamivir
resistance H275Y mutation on enzymatic properties and viral
fitness of the Bris07 H1N1 strain. Noteworthy, our results suggest
that total NA activity was more likely predictive of in vitro and in vivo
viral fitness than the enzyme affinity (Km) parameter. Whether the
Q222R mutation is also deleterious in the absence of H275Y was
not investigated here; however, in a previous work, influenza A/
Paris/497/2007 (222Q/275H) and A/Solomon Islands/3/2006
(222R/275H) seasonal H1N1 isolates grew to comparable titers in
in vitro kinetics experiments [11]. Although clinical 2009 pandemic
H1N1 variants containing such permissive mutations have not
been reported, a computational approach had recently led to the
identification of R257K and T289M as potential secondary
mutations in that context [20]. Thus, monitoring for resistance in
influenza viruses should take into consideration not only NA
resistance-mutations themselves but also permissive/secondary
ones as the latter may significantly affect the clinical and
epidemiological impacts of seasonal or pandemic influenza viruses.
Materials and Methods
Ethics Statement
All procedures were approved by the Institutional Animal Care
Committee at Laval University according to the guidelines of the
Canadian Council on Animal Care.
Rescue of recombinant viruses
Reverse transcription-PCR using universal influenza primers [21]
was used to amplify the eight genomic segments of an oseltamivir-
susceptible A/Quebec/15230/08 (H1N1) isolate whose HA and NA
genes shared respectively 99.53% and 99.71% nucleotide identity
with those of the influenza A/Brisbane/59/2007 vaccine strain [10].
All segments were cloned into the pJET plasmid (Fermentas,
Burlington, ON, Canada) and sequenced. Sequence analysis
Figure 5. Mean viral titers in nasal wash samples of infected and contact ferrets. Mean viral titers 6 standard deviations were determined
in nasal washes by using standard plaque assays in groups of 4 index ferrets infected with 1.25610
5 PFU of recombinant A/Brisbane/59/2007-like
wild-type (WT) virus as well as H275Y and H275Y/Q222R mutants (A) and in groups of 4 naı ¨ve ferrets that were placed in direct contact with index
ferrets 24 h later (B).*P,0.05 and **P,0.01 for differences in viral titers when compared to the recombinant WT virus.
doi:10.1371/journal.ppat.1002431.g005
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(M) and asparagine (N) residues at residues 275, 222, 234 and 344
(N1 numbering), respectively, of the NA protein. The PB1, PB2 and
PAsegmentsweresub-clonedintopLLBG whereasthe HA,NA,NP,
M1/M2 and NS1/NS2 segments were sub-cloned into pLLBA
bidirectional expression/translation vectors as described [22]. The
pLLBA plasmid containing the NA gene was used for the
introduction of the H275Y mutation using appropriate primers and
the QuikChangeTM Site-Directed Mutagenesis kit (Stratagene, La
Jolla, CA). The resulting pLLB-NA275Y mutant plasmid was then
used for reverting potential compensatory mutations (Q222R,
M234V or N344D) as described above. All recombinant plasmids
were sequenced to confirm the absence of undesired mutations. The
eight bidirectional plasmids were cotransfected into 293T human
embryonic kidney cells using the LipofectamineTM 2000 reagent
(Invitrogen, Carlsbad, CA) as previously described [23]. Supernatants
were collected 72 h post-transfection and used to inoculate ST6Gal1-
MDCK cells kindly provided by Dr. Y. Kawaoka, University of
Wisconsin, Madison, WI). The recombinant wild-type (WT) and
H275Y, H275Y/Q222R, H275Y/M234V and H275Y/N344D
mutant viruses were subsequently sequenced and titrated by standard
plaque assays in ST6Gal1-MDCK cells.
NA enzyme kinetics assays
A fluorometric based assay using MUNANA (Methylumbelli-
feryl-N-acetylneuraminic acid) (Sigma, St-Louis, MO) as substrate
was performed to determine total NA enzymatic activity per
infectious virus [24]. Briefly, recombinant viruses were standard-
ized to an equivalent dose of 10
6 plaque forming-units (PFU)/ml
and incubated at 37uC in 50-ml reactions with different
concentrations of MUNANA. The final concentration of the
substrate ranged from 0 to 3000 mM. Fluorescence was monitored
every 90 s for 53 min (35 measures). The Michaelis-Menten
constant (Km) and the relative NA activity (Vmax) were calculated
with the Prism software (GraphPad, version 5), by fitting the data
to the Michaelis-Menten equation using nonlinear regression [25].
Cell surface NA activity
Recombinant NA plasmids and pCAGGS-PA, -PB1, -PB2 and -NP
plasmids were used to co-transfect 293T cells in order to express
recombinant NA enzymes [26]. Twenty-four hours after transfection,
the cells were briefly treated with trypsin-EDTA and neutralized by
the addition of serum followed by centrifugation at 3000 RPM for
5 min. After washing twice with PBS, the cells were resuspended in a
n o n - l y s i n gb u f f e r( 1 5m MM O P S ,1 4 5m Ms o d i u mc h l o r i d e ,2 . 7m M
potassium chloride and 4 mM calcium chloride, adjusted to pH 7.4)
a n du s e di na nN Aa s s a yu s i n gt h eM U N A N As u b s t r a t e[ 1 3 ] .
NA inhibition assays
The drug resistance phenotype was determined by NA inhibition
assays using the MUNANA substrate as previously described [26],
with minor modifications. Briefly, recombinant viruses were
standardized to a NA activity ten-fold higher than that of the
background and then incubated with serial three-fold dilutions of
the drugs (final concentrations ranging from 0 to 1800 nM),
including oseltamivir carboxylate (Hoffmann-La Roche, Basel,
Switzerland), zanamivir (GlaxoSmithKline, Stevenage, UK) and
peramivir (BioCryst, Birmingham, AL). The 50% inhibitory
concentration (IC50) was determined from the dose-response curve.
In vitro replication kinetics experiments
Replicative capacities of the recombinant viruses were evaluated
by infecting ST6Gal1-MDCK cells with a multiplicity of infection
(MOI) of 0.001 plaque-forming units (PFUs)/cell. Supernatants
were collected every 12 h until 60 h PI and titrated by plaque
assays. The mean viral plaque area of recombinant viruses was
determined from a minimum of 16 plaques obtained after 60 h of
incubation under agarose overlay using the ImageJ software
(version 1.41), developed by Wayne Rasband of the National
Institutes of Health as previously described [25].
Ferret studies
Groups of 4 seronegative (900–1500 g) male ferrets (Triple F
Farms, Sayre, PA) were lightly anesthetised by isoflurane and
received an intranasal instillation of 1.25610
5 PFUs of the
recombinant Bris07-like WT, H275Y or H275Y/Q222R variants.
Temperature of ferrets was measured by rectal thermometers
every day until day 10 PI. Ferrets were weighed daily and nasal
wash samples were collected from animals on days 2, 4 and 6 PI.
Virus titers from nasal wash samples were determined by plaque
assays using ST6Gal1-MDCK cells. Serum samples were collected
from each ferret before intranasal infection and on day 14 PI to
evaluate specific antibody levels against the seasonal Bris07 strain
using standard HAI assays. To evaluate contact-transmissibility,
inoculated-contact animal pairs were established by placing a
naı ¨ve ferret into each cage 24 h after inoculation of the index
ferret [27]. Contact animals were monitored for clinical signs and
nasal wash and serum samples were collected as described above
for determination of viral titers and serological status, respectively.
Statistical analyses
NA kinetic parameters (Km and Vmax values), NAI IC50 values
and viral titers in vitro and in nasal washes of ferrets were compared
by one-way ANOVA analysis of variance, with the Tukey’s
multiple comparison post test. The amount of NA activity on the
cell surface and plaque sizes of the recombinants were compared
to those of the WT virus and/or the H275Y mutant by the use of
unpaired two-tailed t tests.
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